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Abstract
Elevation of the proinflammatory cytokine Interleukin-1 (IL-1) is an integral part of the local tissue
reaction to central nervous system (CNS) insult. The discovery of increased IL-1 levels in patients
following acute injury and in chronic neurodegenerative disease laid the foundation for two decades
of research that has provided important details regarding IL-1's biology and function in the CNS.
IL-1 elevation is now recognized as a critical component of the brain's patterned response to
insults, termed neuroinflammation, and of leukocyte recruitment to the CNS. These processes are
believed to underlie IL-1's function in the setting of acute brain injury, where it has been ascribed
potential roles in repair as well as in exacerbation of damage. Explorations of IL-1's role in chronic
neurodegenerative disease have mainly focused on Alzheimer disease (AD), where indirect
evidence has implicated it in disease pathogenesis. However, recent observations in animal models
challenge earlier assumptions that IL-1 elevation and resulting neuroinflammatory processes play a
purely detrimental role in AD, and prompt a need for new characterizations of IL-1 function.
Potentially adaptive functions of IL-1 elevation in AD warrant further mechanistic studies, and
provide evidence that enhancement of these effects may help to alleviate the pathologic burden of
disease.
Introduction
Interleukin-1 (IL-1) comprises a pleiotropic cytokine fam-
ily capable of numerous actions in the central nervous sys-
tem (CNS). IL-1 classically refers to a 17 kilodalton (kDa)
polypeptide existing in two distinct isoforms, IL-1α and
IL-1β, although other members of the IL-1 family have
recently been proposed [1]. Although IL-1α and IL-1β are
encoded by separate genes sharing some sequence homol-
ogy, they elicit similar biological actions. In addition to
these two IL-1 receptor agonists, a native IL-1 receptor
antagonist (IL-1ra) also maps to the IL-1 gene cluster on
human chromosome two. All three proteins are produced
as precursors, of which pro-IL-1α and pro-IL-1ra possess
biological activity. Pro-IL-1β, however, requires cleavage
by caspase-1 (IL-1β converting enzyme, ICE) to become
biologically active. Details about the structure and regula-
tion of these family members, as well as information
about many of their actions can be found in recent reviews
[2-4].
All known actions of IL-1 are mediated by a single biolog-
ically active 80 kDa cell surface receptor, the type I IL-1
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rodent brain, with levels generally highest in neuronal
rich areas including the dentate gyrus, the pyramidal cell
layer of the hippocampus, and the hypothalamus [6,7].
Binding of IL-1 agonists to IL-1R1 requires association
with an accessory protein to elicit downstream signal
transduction that includes activation of nuclear factor-
kappa B (NFκB) and mitogen-activated protein (MAP)
kinase pathways [8,9]. While all known biological func-
tions of IL-1 are attributable to IL-1 interactions with IL-
1R1, some studies suggest that alternate functional IL-1
receptors may exist in the CNS [10,11].
The evolutionary importance of IL-1 activity within the
brain is highlighted by the presence of two distinct endog-
enous regulatory pathways. IL-1ra is a competitive antag-
onist of IL-1R1 that selectively binds, but fails to trigger
receptor association with the accessory protein resulting
in blockade of all known actions of IL-1. A second 68 kDa
receptor, the type II IL-1 receptor (IL-1RII), may serve as a
decoy as it binds all IL-1 ligands but lacks an intracellular
domain and has no demonstrated signaling function [12].
Further description of the IL-1 regulatory pathways can be
found in two recent comprehensive reviews [1,13].
IL-1 actions within the CNS
IL-1 was the first cytokine identified with actions on the
brain [14,15]. Its ability to elicit fever after peripheral
administration led to early descriptions of IL-1 as the
"endogenous pyrogen". The research that followed has
implicated IL-1 in a diverse array of physiologic and path-
ologic processes within the mammalian CNS, and has
earned IL-1 status as a prototypic pro-inflammatory
cytokine [13,16,17]. Generally speaking, the actions of IL-
1 in the CNS are attributed to either responses of the neu-
roendocrine system or the local tissue microenvironment.
In response to homeostatic threats in mammals, increased
IL-1 levels activate the hypothalamo-pituitary-adrenal
(HPA) axis and are central to elicitation of sickness behav-
iors. The downstream effects of this neuroendocrine sys-
tem stimulation likely underlie the ability of IL-1 to
modulate processes such as appetite, body temperature,
epilepsy, and sleep/wake cycles in mammals [16,18-20].
This review will focus on IL-1 as a key regulator of local tis-
sue responses to injury and disease in the CNS, with
emphasis on its role in neuroinflammation.
Expression of IL-1 in injury and disease
Initial evidence that IL-1 may play a key role in local brain
tissue reactions came from demonstrations of elevated IL-
1 expression in a diverse array of CNS diseases. In
humans, IL-1 is elevated in brain tissue and cerebrospinal
fluid (CSF) from patients who succumbed to brain injury
or stroke [21]. This pattern of expression was further
extended to animal models of CNS injury where paren-
chymal IL-1 mRNA and protein levels are elevated in
experimental models of ischemia, excitotoxicity, infection
and traumatic brain injury in rodents. While IL-1α and IL-
1β are barely detectable in either normal human or rodent
brain, they are rapidly induced within minutes of acute
experimental injuries [reviewed in [1,3,22]].
In addition to initial demonstrations of IL-1 elevations
following acute injuries, similar observations have been
made in a number of chronic neurodegenerative disor-
ders. IL-1 elevations have been reported within brain
lesions from patients with Alzheimer's disease (AD), Mul-
tiple Sclerosis (MS), Down's Syndrome and HIV-associ-
ated dementia [17,23-25]. Furthermore, increased IL-1
has been detected in CSF samples in MS, Parkinson's and
Creutzfeldt-Jakob disease (CJD) [26-28]. These findings
have since been reproduced in corresponding animal
models of disease for AD, MS and CJD [29-33].
Sources and targets of IL-1 expression
IL-1 is both expressed by and targeted to many different
cell types within the CNS. Microglia express ICE, and in
response to injury are thought to produce both the initial
burst and highest levels of IL-1 production [34]. IL-1 can
also be produced by astrocytes, endothelial cells, infiltrat-
ing leukocytes, neurons and oligodendrocytes [4,35,36].
In turn, IL-1 can feed back on its original cellular sources
but is thought to exert its primary actions on microglia,
astrocytes and endothelial cells [2].
Neuroglia and endothelial cells produce a myriad of sign-
aling molecules in response to IL-1 stimulation. These
include pro-inflammatory cytokines, chemokines, adhe-
sion molecules, prostaglandins, reactive oxygen species,
nitric oxide, and matrix metalloproteases. Notably, IL-1
induces expression of the pro-inflammatory cytokines
tumor necrosis factor alpha (TNF-α) and Interleukin-6
(IL-6) as well as the enzyme cyclooxygenase-2 (COX-2) in
both astrocytes and microglia in culture [4,37,38]. These
inflammatory mediators have been implicated in the
propagation of a number of CNS injuries and diseases
[39].
IL-1β and neuroinflammation
Neuroinflammation is traditionally defined as the brain's
innate immune response to injury. The hallmarks of a
neuroinflammatory response are phenotypic glial activa-
tion and de novo production of immune signaling mole-
cules. Both astrocytes and microglia undergo cellular
hypertrophy with increased expression of cell-surface
immune modulatory proteins, including those of the
major histocompatibility complex (MHC). These changes
are accompanied by increased synthesis and release of
pro-inflammatory cytokines and chemokines.Page 2 of 12
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roinflammatory processes in vivo. Exposure of the rodent
brain to IL-1β elicits rapid, robust activation of both astro-
cytes and microglia. In addition, single bolus injection or
parenchymal expression of IL-1β in rodents increases
expression of pro-inflammatory cytokines, leukocyte
chemotactic chemokines, cell surface adhesion molecules,
cyclooxygenases and matrix metalloproteases within the
brain parenchyma [40-45]. Importantly, IL-1β is capable
of triggering further increases in it's own expression as evi-
denced by murine IL-1β induction following human IL-
1β administration or expression in the brain [45,46]. By
feeding back upon itself, small localized elevations in IL-
1 may be sufficient to drive potent neuroinflammatory
changes in the brain. Further evidence for a central role of
IL-1 in neuroinflammation has been provided in IL-1R1
knockout mice where lack of IL-1 signaling in the setting
of penetrating brain injury causes dramatic attenuation in
microglial and astrocytic activation as well as IL-6 and
COX-2 production [47,48].
IL-1 and leukocyte recruitment
In addition to elaboration of a robust neuroinflammatory
response in the CNS, IL-1 elevations have been implicated
in trafficking of peripheral immune cells to the brain. The
normal, healthy CNS has relatively few, if any leukocytes
[49]. However, cellular populations within the brain can
quickly change following injury. The inflammatory
response that follows CNS insults such as infection or
injuries caused by trauma or ischemia often features rapid
infiltration of leukocytes into the brain [50-52].
IL-1β expression is a powerful stimulus for leukocyte
recruitment to the CNS. Either single bolus injection or
localized expression of IL-1β within the rodent brain is
capable of overriding the brain's intrinsic resistance to leu-
kocyte recruitment, resulting in rapid cellular infiltration
of the parenchyma. Cell types recruited include neu-
trophils, CD4+ and CD8+ T-cells, dendritic cells, and cells
of the monocyte lineage [40,43,44,46,53,54]. This leuko-
cyte infiltration is dependent on IL-1R1, and can be signif-
icantly reduced following administration of IL-1ra
[44,53,55,56]. The ability of IL-1β to drive enhanced
expression of monocyte chemoattractant protein-1 (MCP-
1; CCL2) by astrocytes and intercellular adhesion mole-
cule-1 (ICAM-1) on vascular endothelial cells within the
brain is thought to facilitate parenchymal cellular recruit-
ment [40,44]. Indeed, adenoviral overexpression of IL-1ra
following experimental ischemia reduces ICAM-1 expres-
sion and leukocyte infiltration of the brain [57].
Neutrophils play a vital role in the innate arm of the
immune response that rapidly develops at sites of injury
and infection. While primarily recognized for destruction
of invading pathogens, neutrophils can also shape
immune responses [58]. The chemokines of the ELR+ CXC
family are potent stimuli for the recruitment and activa-
tion of neutrophils in peripheral and CNS inflammatory
responses, and are upregulated by acute IL-1β stimuli [59-
63]. In mice, the most potent and well defined members
of this family are keratinocyte-derived chemokine (KC,
CXCL1) and macrophage inflammatory protein 2 (MIP-2,
CXCL2) which are thought to signal exclusively through
the CXCR2 receptor [50,60,63-65]. Interestingly, chronic
IL-1β expression can serve as a long-lasting stimulus for
MIP-2 and KC induction as well as neutrophil recruitment
to the brain. Using a mouse model of chronic hippocam-
pal human IL-1β overexpression, we observed neutrophil
infiltration of the brain parenchyma months after initia-
tion of transgene activation. This neutrophil recruitment
appeared to be dependent on signaling through the
CXCR2 receptor, as it was absent in CXCR2 knockout
mice [44].
Leukocyte recruitment to the CNS is highly restricted by
presence of the blood-brain barrier (BBB), which is cred-
ited for the virtual absence of leukocytes within the
healthy brain parenchyma [66]. Although not thought to
be necessary nor sufficient for leukocyte infiltration of the
CNS, breakdown of the BBB is believed to potentiate cel-
lular recruitment to the brain [49]. Experimentally
induced elevations of IL-1β levels in the brain cause dis-
ruptions in the BBB, which may underlie its effectiveness
as a leukocyte recruitment stimulus [41,43,44,54]. Neu-
trophils have been implicated in mediating this effect
based on a study in rats where administration of anti-
CINC-1 (CXCL1) neutralizing antibodies attenuated neu-
trophil recruitment and BBB breakdown downstream of
intracerebral IL-1β injections [41]. However, recent work
in our laboratory indicates that IL-1β can influence BBB
integrity even in the relative absence of neutrophil recruit-
ment. More specifically, we observed significant leakage
of albumin bound Evan's blue dye into the brain paren-
chyma of mice engineered to chronically express human
IL-1β in a sustained manner, which was not altered in ani-
mals lacking the CXCR2 receptor [44]. The precise mech-
anisms of IL-1β mediated changes in BBB permeability
remain unclear. Further studies are needed to elucidate
this phenomenon, as it may be important in the patho-
genesis of CNS injury and disease.
Learning, memory, and IL-1
In addition to its role in elaboration of neuroinflamma-
tion and leukocyte recruitment, local expression of IL-1
has been implicated in impairment of hippocampal
dependent memory processing [67]. IL-1β activity is
thought to be closely tied to the process of memory con-
solidation based on demonstrations of increased IL-1β
expression in vitro and in vivo during long-term potentia-
tion (LTP), a process that is believed to underlie hippoc-Page 3 of 12
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mammals [68]. At sufficient concentrations, IL-1β is capa-
ble of blocking hippocampal LTP [69]. Also, injection of
lipopolysaccharide (LPS), a potent inducer of IL-1β
expression by microglia, into the rat hippocampus results
in learning and memory deficits [70]. Conversely, block-
ade of IL-1R1 in rats using adenoviral expressed IL-1ra
leads to facilitation of short and long-term memory in an
inhibitory avoidance task [71]. Based on these data, it is
feasible that IL-1 elevations, as occur following CNS inju-
ries and during neurodegenerative disease, might lead to
impairments in learning and memory. This may help
explain the prominent memory deficits characteristic of
AD and HIV-associated dementia.
The contribution of IL-1 to acute CNS injury
The elevation of IL-1 expression following a diverse array
of acute brain injuries coupled with its ability to elicit
diverse inflammatory changes as previously discussed,
suggests that it may contribute to the pathogenesis of CNS
injury. Indeed, data from head injury victims as well as in
acute experimental brain injury paradigms has provided
strong evidence in support of this [21]. To date most stud-
ies have focused on the CNS actions of IL-1β, rather than
IL-1α, based on its more rapid induction following injury
[16]. A number of studies have demonstrated that admin-
istration of IL-1β concurrent with experimental ischemia
is capable of exacerbating injury [1,72]. Conversely,
ischemic damage is greatly reduced by knockout of IL-1α
and IL-1β, administration of IL-1 blocking antibodies, or
disruption of interleukin-1 converting enzyme function
[2,73,74]. Interestingly, there is some evidence that IL-1
may influence ischemic injury independent of IL-1R1
[11]. In traumatic brain injury, neuronal damage is simi-
larly reduced by administration of IL-1ra [75]. Based on
the ability of exogenously administered IL-1ra to attenu-
ate experimental ischemic injury and cross the BBB, ther-
apy with human IL-1ra has been investigated in a Stage II
clinical trial of stroke [76-78].
Increased levels of endogenous IL-1ra and IL-1RII are
likely to be important mechanisms for regulation of IL-1
activity following brain injury. IL-1ra is rapidly induced
following experimental injury, and blockade of endog-
enous production leads to exacerbation of neurotoxicity
following ischemic injury in rodents [74,79]. Increased
expression of IL-1RII, the biologically inactive "decoy" IL-
1 receptor, has been demonstrated following injection of
IL-1β into the brain parenchyma and may also serve to
limit the biological function of IL-1 [12].
In addition to data implicating IL-1 in exacerbation of
acute injury, other studies have provided evidence for
beneficial effects of IL-1 signaling within the brain. IL-1
has been associated with neuroprotective mechanisms in
rodent primary neuron cultures which may be mediated
in part by production of survival signals such as nerve
growth factor (NGF) [80-82]. IL-1 signaling has also been
implicated in re-myelination of the CNS after cuprizone
demyelination injury, which may be due in part to IL-1
mediated stimulation of oligodendrocyte proliferation
[35,83]. Finally, absence of IL-1R1 has been associated
with deficiencies in hippocampal dependent spatial learn-
ing but it is unclear if this is a result of specific beneficial
influences of IL-1 on the intact nervous system or repre-
sents developmental alterations in the knockout mouse
[84].
Mechanisms of IL-1 induced neuronal damage
Due to its pleiotropic actions in the brain it has been dif-
ficult to pinpoint the mechanisms by which IL-1 exacer-
bates acute CNS injuries. In general, it does not appear
that IL-1β is capable of triggering direct neurotoxicity
when administered to the healthy adult rodent brain [16].
For example, chronic hippocampal overexpression of
human IL-1β in mice does not engender overt neurotoxic-
ity or changes in measures of neuronal integrity [44]. In
rats, IL-1β induced neurotoxicity has been reported fol-
lowing single bolus injection or adenoviral mediated
expression of IL-1β in the substantia nigra or hippocam-
pus, respectively [46,85,86]. However, these studies in rats
may have been confounded by tissue injury resulting from
parenchymal injections, viral induced inflammation, or
the use of non-physiologic doses of IL-1β. It is also possi-
ble that the capacity of IL-1β to mediate direct neurotox-
icity may be a species-specific phenomenon. In vitro, IL-
1β exposure does not affect the viability of pure mouse or
rat neuronal cultures and can reduce excitotoxin induced
neurotoxicity [81,82]. However, in rat mixed glial/neuro-
nal cultures IL-1β has been reported to cause neurotoxic-
ity through downstream free radical release [87].
Neutrophils have emerged as possible perpetrators of neu-
ronal damage following acute brain insults downstream
of IL-1β elevations [40,41,43,53]. Neutrophils are rapidly
recruited following CNS injury, present at the time of neu-
ronal death, and can trigger tissue damage through gener-
ation of toxic free radicals, proteolytic enzymes and pro-
inflammatory cytokines such as IL-1β and TNF-α [52]. In
vitro, co-cultures of rat neutrophils and primary hippoc-
ampal neurons demonstrate neurotoxicity in the absence
of physiologic insults as well as exacerbation of kainic
acid excitotoxicity [88]. In vivo, constitutive CNS overex-
pression of the chemokine KC results in striking recruit-
ment of neutrophils to multiple brain regions and early
neurological demise [89]. Depleting neutrophils or limit-
ing their infiltration through ICAM-1 gene ablation atten-
uates experimental ischemic injury [52,90]. Despite these
observations, recruitment of neutrophils does not appear
to be sufficient for neurotoxicity. This point is supportedPage 4 of 12
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overt neurotoxicity, synaptic damage, or loss of acetylcho-
line fibers was observed after 2 weeks or 2 months of sus-
tained IL-1β induced neuroinflammation accompanied
by prominent neutrophil infiltrates [44]. However, this
study was limited to neuroinflammation in the dentate
gyrus in the absence of concomitant injury, and it is pos-
sible that neurons in other brain regions may be more sus-
ceptible to neutrophil-mediated effects.
Neuroinflammation and AD
Neuroinflammation is now recognized as a fundamental
response of the CNS not only to acute injury, but also to
chronic neurodegenerative disease. This is perhaps no bet-
ter demonstrated than in AD, where the severity of the
neuroinflammatory response parallels the disease course
[91,92]. Neuroinflammation can be considered part of a
characteristic pathologic triad of AD that includes amy-
loid plaques and neurofibrillary tangles. The neuroin-
flammatory phenotype in AD is characterized by robust
activation of microglia and astrocytes in the vicinity of
plaques, endogenous expression of pro-inflammatory
cytokines, cell adhesion molecules, and chemokines
[17,93-96]. These changes are thought to result from glial
reaction to events related to ongoing deposition of amy-
loid β (Aβ) [97-99].
Epidemiological studies of nonsteroidal anti-inflamma-
tory drug (NSAID) users lent credence to initial hypothe-
ses as to the role of neuroinflammation in AD. Early
observations among identical twins discordant for AD
onset showing that those receiving anti-inflammatory
therapy had delays in disease onset provided strong evi-
dence for a detrimental role of neuroinflammation in AD
pathogenesis [100]. Soon thereafter, additional case-
based and longitudinal epidemiologic studies confirmed
these findings, and demonstrated substantial reductions
in disease incidence among patients on long-term regi-
mens of NSAIDs [101-103]. In fact, recent meta-analysis
has revealed as much as a 50% reduction in the risk of
acquiring disease among chronic NSAID users [104]. This
data led to a surge of research activity directed at elucidat-
ing the role of inflammation in AD and other chronic neu-
rodegenerative disorders in hopes of designing new
effective anti-inflammatory therapies for disease.
Unfortunately, clinical trials of traditional anti-inflamma-
tory agents for treatment of patients with AD have failed
to demonstrate efficacy [105-110]. Also, the only trial
designed to directly address the hypothesis that chronic
NSAID use can prevent AD in cognitively normal subjects
failed to demonstrate a protective effect [111]. Drawing
conclusions from these studies is complicated by the
selection and dose of NSAIDs used, length of trials and
overall designs [112]. Furthermore, the patient popula-
tions in these trials differ from their epidemiologic coun-
terparts as patients in the latter were being treated with
NSAIDs for inflammatory disorders which may have
modified their risk of acquiring AD. Overall, the stark con-
trast between these results and the early epidemiological
studies of chronic NSAID users suggests a complex role for
neuroinflammation in AD.
Transgenic mouse models of AD harboring familial amy-
loid precursor protein (APP) mutations have recapitu-
lated in part the intimate relationships between
neuroinflammation and disease pathogenesis. In
APPV717F mice astrocyte activation was evident before
plaques were detected, and in the Tg2576 mouse model
increased microglial density was observed in regions of Aβ
deposits [113,114]. Similar neuroinflammatory changes
have been observed in other murine models of AD,
including the APP/PS1 double transgenic and APP/PS1/
Tau triple transgenic (3xTg-AD) mice [115-117]. Finally,
NSAID administration reduced both plaque pathology
and neuroinflammatory measures in the Tg2576 mice
[32].
Possible roles for IL-1 in AD
IL-1 elevations became closely tied to AD pathogenesis
soon after the discovery of prominent neuroinflammation
in AD brain. Increased IL-1 expression in reactive micro-
glia surrounding amyloid plaques provided the initial
indication that IL-1 may be associated with AD pathogen-
esis [17]. Since that time, IL-1β elevations have been
detected in the brains of aged AD mouse models and
plaque associated microglia [31,32]. Microglial IL-1 activ-
ity was later tied to the evolution of plaques in AD [118].
In Down's syndrome, where patients are predisposed to
AD neuropathological changes, IL-1 elevation and neu-
roinflammation precede by years the formation of
plaques [119]. Additionally, specific polymorphisms in
the IL-1α and IL-1β genetic loci were shown to be associ-
ated with increased disease risk in certain patient popula-
tions [reviewed in [120,121]]. These associations, in
addition to observations of IL-1 elevations in AD patients,
provided the key evidence for a central role of IL-1 in dis-
ease pathogenesis. However, recent meta-analysis has not
supported a clear association between IL-1 genetic loci
and AD when the data is examined as a whole [122].
IL-1 has been implicated in both the initiation and prop-
agation of neuroinflammatory changes seen in AD
through several lines of indirect evidence [reviewed in
[39,123]]. Obviously, the known ability of IL-1 to drive
robust neuroinflammatory changes in the acute setting
adds to its attractiveness as a prime candidate for these
actions. In AD, neuronal injury or insults including amy-
loid deposition may trigger a self-propagating cytokine
cycle, which when chronically induced initiates a viciousPage 5 of 12
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further neuronal and synaptic dysfunction and Aβ plaque
accumulation [99]. In support of this idea, cultured
human monocytes and mouse microglia produce IL-1β in
response to Aβ exposure or, to a greater extent, to secreted
fragments of β-APP [124,125]. In other tissue culture stud-
ies IL-1 has been shown to increase β-APP mRNA expres-
sion, translation, and processing perhaps through
enhanced gamma secretase activity [126-130]. In addi-
tion, IL-1β injection into rat brain results in elevation of
β-APP [131]. Furthermore, IL-1ra knockout mice demon-
strate enhanced human amyloid-beta induced neuropa-
thology, suggesting the unopposed action of IL-1 as a
likely culprit [132]. Although these findings are largely in
vitro based, correlations in Alzheimer and control
patients support the idea that these basic mechanisms
occur in the disease itself.
In addition to association with modulation of β-APP
processing, IL-1 activity has been tied to exacerbation of
neurofibrillary tangles. Implantation of slow release IL-1β
pellets in rats led to microglial activation and MAPK-p38-
mediated hyperphosphorylation of tau protein, which is
thought to contribute to microtubule destabilization and
ultimately to formation of neurofibrillary tangles
[133,134]. Analogous studies have been reported in corti-
cal neuron cultures [135]. Microglial activation may be
responsible for these effects as suggested by a recent study
of synapse loss in a mouse tauopathy model [136]. Fur-
ther support for IL-1β mediated activation of microglia
and resultant tau hyperphosphorylation has been indi-
rectly provided in the 3xTg-AD mouse model which
expresses human mutated forms of tau, presenilin-1 and
APP, and is characterized by both Aβ and tau pathology.
Intraperitoneal LPS injections elicited significant IL-1β
induction, microglial activation and accelerated the time
course of tau hyperphosphorylation. Interestingly, LPS
activity did not affect APP processing or Aβ deposition
[137].
A beneficial role for neuroinflammation in AD
While epidemiologic and experimental studies lend
strong support for neuroinflammatory responses as driv-
ers of AD pathogenesis, recent work also supports a bene-
ficial role for such reactions [reviewed in [98]]. A number
of reports have provided evidence that activation of
microglia and their subsequent degradation of amyloid
plaques may underlie this phenomenon. Direct injection
of LPS into the CNS, which drives IL-1β synthesis and
robust microglial activation, yields reductions of Aβ levels
and plaque load [138-140]. Microglial activation has also
been suggested to underlie enhanced plaque clearance in
other transgenic AD models following treatment with
either a modified nitric oxide-releasing NSAID (NCX-
2216) or transforming growth factor beta overexpression
(TGF-β) [141,142]. Conversely, inhibition of microglial
activation with minocycline can increase Aβ deposition
[143]. Although these reports and others suggest a benefi-
cial role of microglial activation in mouse models of AD,
it is worth noting that LPS stimulated neuroinflammation
has also been associated with increased Aβ deposition
[144,145].
Microglial activation is thought to reduce plaque burden
through phagocytosis of Aβ peptides. There is substantial
evidence for plaque associated microglia as phagocytosing
scavengers of amyloid in vivo [146]. Indeed, the efficacy
of antibody-mediated plaque clearance in AD mouse
models appears in part to be mediated by enhanced
phagocytosis by microglia [147,148]. In support of this,
interference with microglial activation during Aβ immu-
notherapy reduced clearance of fibrillar deposits [149].
Infiltration of peripheral immune cells into sites of
pathology, though not reported in AD itself, may enhance
the beneficial effects of microglial mediated plaque clear-
ance. It has been convincingly demonstrated, using green
fluorescent protein (GFP) expressing bone marrow trans-
plants in AD mouse models, that a proportion of activated
microglia adjacent to amyloid plaques are in fact recruited
from bone marrow-derived myeloid populations
[150,151]. LPS administration enhances the seeding of
bone marrow-derived myeloid cells in the brain which
may in part explain its ability to enhance amyloid plaque
clearance [150]. Selective elimination of bone marrow-
derived myeloid cells exacerbates plaque pathology in AD
models, and providing strong evidence that this micro-
glial sub-population is efficient at degrading plaque
[151,152]. Interestingly, an infiltrative cell type with den-
dritic cell-like characteristics appears to be particularly
important in this process [153]. Taken altogether, these
results suggest that the beneficial effects of neuroinflam-
mation may in part result from increased recruitment of
bone marrow-derived cells to the brain.
A new view of IL-1's role in AD?
Since the original observations of IL-1 elevation in AD two
decades ago, a body of evidence has implicated this proin-
flammatory cytokine as contributing to the pathogenic
processes characteristic of disease. Much of this data has
relied on indirect evidence and extrapolation from studies
in tissue culture and acute injury paradigms. As is the case
for neuroinflammation, contemporary studies in animal
models of AD are challenging our original assumptions as
to the role of IL-1 in AD.
Substantial support for an adaptive role of IL-1 elevation
comes from a model developed in our laboratory to spe-
cifically address the function of chronic IL-1 driven neu-
roinflammation in AD pathology. When IL-1β wasPage 6 of 12
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PS1 transgenic animals, we witnessed a surprising reduc-
tion in both plaque pathology and insoluble amyloid
peptide without evidence of effects on Aβ processing or
APP expression. There was also a striking increase in num-
bers of plaque associated myeloid cells, suggesting
enhanced phagocytosis of Aβ by microglia or infiltrating
myeloid cells [45]. A limitation of this study is the use of
a heterologous APP promoter, as this does not allow for
interplay between inflammation and the APP promoter as
discussed earlier. However, IL-1β overexpression was not
associated with increased levels of murine APP mRNA
[45].
The initial stimulus for elevation of IL-1 in AD is likely the
result of exposure of microglia to injured neurons, β-APP,
and its cleavage product Aβ as has been demonstrated
both in vitro and in vivo [125,151]. Microglia chronically
exposed to these stimuli during the course of disease likely
mount sustained elevations in IL-1 and drive a self-perpet-
uating cycle of IL-1 overexpression in the brain paren-
chyma leading to chronic neuroinflammation [45]. As
highlighted above, IL-1 elevation may potentiate plaque
degradation by enhancing microglial activation and
phagocytic activity, as well as seeding of peripheral phago-
cytic cells to areas of plaque deposition [44]. Despite this
evidence pointing toward an important function of IL-1 in
AD pathogenesis, a recent study in the Tg2576 AD mouse
model failed to detect any influence of IL-1R1 knockout
on either Aβ deposition or the efficacy of passive immu-
notherapy [154]. However, these results must be inter-
preted with caution as IL-1R1 knockout animals may be
affected by compensatory changes during development.
At the present time our understanding of the relationship
between neuroinflammation, IL-1, and AD is evolving.
The downstream consequences of IL-1 elevation in AD
likely involve a balance between the beneficial and detri-
mental functions highlighted in this review (Figure 1).
Failures of recent anti-inflammatory trials in the treatment
of AD may be in part explained by blockade of both ben-
eficial and detrimental neuroinflammatory processes in
the course of disease. Current findings are consistent with
the idea that strategies aimed at enhancing beneficial
components of neuroinflammatory pathways in chronic
neurodegenerative disease may hold promise in the devel-
opment of new therapies.
Conclusion
This review highlights recent scientific studies of IL-1
activity in neuroinflammation and AD, and paints a com-
plex picture of IL-1 function in the local tissue response of
the brain to injury and disease. A clearer understanding of
IL-1's role is unfolding, yielding observations of both
helpful and harmful effects in experimental paradigms.
This is particularly true in regard to the pathogenesis of
AD, where recent observations urge a reexamination of
original assumptions as to the role of IL-1 in disease. This
emerging understanding of IL-1's contribution to the
pathogenesis of CNS insults has identified possible roles
in triggering adaptive innate immune processes during the
course of chronic neurodegenerative disease. IL-1 can no
longer be regarded as simply the villain in the setting of
brain injury and disease, but instead might be understood
as a factor that can influence the balance between benefi-
cial and detrimental outcomes. Potentiation of such adap-
tive IL-1 driven responses in chronic neurodegenerative
A schematic depiction of potential roles of IL-1 in ADFigur  1
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